united therapeutics glp-1 receptor agonist products Frontiers Medicilon's GLP-1 New Drug R&D
Description
A small human proof-of-concept trial reported that semaglutide reduced vastus lateralis cross-sectional area but did not reduce knee-extension strength or grip strength over 12 weeks
With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor
altRx GLP-1 Injections are customized GLP-1 therapy designed for individuals who benefit from a formulation aligned with their specific health goals
Discover if there are generic GLP-1 drugs available and how they can impact diabetes management and weight loss.
ProAct Pharmacy Benefit Management Solutions
